-
2023-508105-24-00
5
2021-11-11
COVID-19
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2023-507728-22-00
3
2021-06-25
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
-
2024-515063-66-00
4
2021-03-30
Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-514010-12-00
1
2020-12-03
Advanced Malignancies
-
2024-510783-23-00
7
2020-10-29
Fallopian Tube Cancer
-
2024-514542-37-00
9
2020-08-13
Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2024-513734-38-00
5
2019-07-03
Prevention of breast cancer in women with a BRCA1 germline mutation
-
2024-515690-10-00
9
2019-05-10
Follicular B-cell non-Hodgkin's lymphoma
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2023-505625-14-00
7
2017-01-31
Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
-
2024-519978-39-00
3
2026-04-17
Kidney trasplants
-
2025-521918-26-00
4
2026-02-11
HIV Infections
-
2024-519641-30-00
4
2026-01-26
Asymptomatic patients with recent HIV-1 infection
-
2023-506146-23-00
4
2025-11-17
Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2025-520629-19-00
3
2025-10-01
HIV Infections